iXCells Biotechnologies USA, Inc., a cell technology company specializing in providing cell-based products and drug discovery solutions to the global academic, biotech and pharmaceutical communities, announced completing key growth initiatives.
The company relocated to new expanded facilities in San Diego, California in July, tripling its footprint for cell product manufacturing, research, and drug discovery services, including tailored production of disease relevant cell models using CRISPR Cas9. iXCells’ chief executive, Dr. Lynn Zhang, commented, “We quickly outgrew our previous space after only a few years and this new facility offers substantially more capacity for scaling production and lab service projects integral to our customers’ preclinical development workflows.”
Dr. Nianwei Lin, the company’s President, added, “This effort is the culmination of almost twelve months of careful planning. I’m immensely proud of all our employees and their contributions in making this relocation highly successful while ensuring minimal interruption to our customer service level. To celebrate this important milestone, we’re planning to announce an exciting open-house event for our customers and suppliers later this year.”
Also in July, the company officially launched its new website, www.ixcellsbiotech.com. iXCells’ Marketing Manager, Luana Meira Williams, commented, “Our new site dramatically increases User experience from product & service browsing through to cart checkout according to UX design best practice. Some of the new features worth mentioning include a powerful global search capability, dynamic product and cell images, related product recommendations, and introduction of a customer referral and loyalty program. Moreover, we incorporated best practice content management systems integrated with our ERP system and marketing automation to deliver optimal functionality and User engagement; we believe customers, business partners, and other Users will be pleased with these new features and benefits.”